Neuropace, Inc. NPCE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$21.57M+13.1% | -$21.47M+20.9% | -$23.99M+14.6% | -$25.94M+13.2% | -$24.81M+21.3% | ||
| $340K+14.5% | $329K+12.3% | $297K+4.2% | $297K+4.2% | $297K+4.2% | ||
| $10.74M+3.6% | $11.09M+7.8% | $11.09M+10.5% | $11.05M+12.0% | $10.37M+4.0% | ||
| $256K+28.6% | $237K+3.9% | $223K-12.5% | $200K-29.1% | $199K-33.0% | ||
| —— | —— | —— | —— | -$2K— | ||
| —— | —— | —— | —— | $3.8M+54.9% | ||
| —— | —— | $6.25M+141% | $5.24M— | $2.42M— | ||
| $499K— | -$730K— | $2.43M— | $2.35M— | —— | ||
| $1.89M— | $3.55M— | $2.25M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$553K-191% | -$414K+22.5% | -$100K-113% | -$113K-114% | -$190K-122% | ||
| $1.75M+9.6% | $1.71M+9.5% | $1.67M+9.4% | $1.63M+9.2% | $1.6M+9.1% | ||
| -$1.92M-14.3% | -$1.86M-14.3% | -$1.8M-14.5% | -$1.74M-14.7% | -$1.68M-14.8% | ||
| -$9.93M+44.5% | -$11.51M+35.9% | -$16.31M+1.1% | -$16.09M+5.8% | -$17.9M-2.1% | ||
| $412K+72.4% | $332K+8.5% | $274K-8.4% | $344K+65.4% | $239K+64.8% | ||
| -$412K-106% | -$332K-104% | $1.73M-83.6% | $3.16M-76.3% | $6.56M-57.3% | ||
| —— | —— | —— | —— | $49.55M— | ||
| $1.5M-6.0% | $1.88M-2.9% | $1.75M-7.3% | $1.78M-4.2% | $1.6M+4.7% | ||
| $491K+6.7% | $543K-38.4% | $547K-33.8% | $562K-29.1% | $460K-39.6% | ||
| —— | —— | —— | —— | $25.36M+200% | ||
| —— | —— | —— | —— | —— | ||
| $5.69M-18.0% | $6.2M-0.5% | $6.67M+22.0% | $7.14M+52.2% | $6.94M+49.9% | ||
| $256K+28.6% | $237K+3.9% | $223K-12.5% | $200K-29.1% | $199K-33.0% | ||
| $340K+14.5% | $329K+12.3% | $297K+4.2% | $297K+4.2% | $297K+4.2% | ||
| —— | —— | —— | —— | —— | ||
| $402K-52.8% | $538K-43.6% | $674K-35.4% | $804K-28.3% | $851K-26.4% | ||
| -$1.92M-14.3% | -$1.86M-14.3% | -$1.8M-14.5% | -$1.74M-14.7% | -$1.68M-14.8% | ||
| —— | —— | —— | —— | —— | ||
| $191K-23.0% | $159K-36.7% | $195K-25.0% | $255K+29.4% | $248K+18.7% | ||
| $1.75M+9.6% | $1.71M+9.5% | $1.67M+9.4% | $1.63M+9.2% | $1.6M+9.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.5M-6.0% | $1.88M-2.9% | $1.75M-7.3% | $1.78M-4.2% | $1.6M+4.7% | ||
| —— | —— | —— | —— | $105K-15.3% | ||
| —— | —— | —— | —— | $387K— | ||
| —— | —— | —— | —— | —— | ||
| -$553K-191% | -$414K+22.5% | -$100K-113% | -$113K-114% | -$190K-122% | ||
| -$1.92M-14.3% | -$1.86M-14.3% | -$1.8M-14.5% | -$1.74M-14.7% | -$1.68M-14.8% | ||
| -$10.25M+43.5% | -$11.75M+35.7% | -$16.58M+1.2% | -$16.43M+4.9% | -$18.14M-2.6% | ||
| -$10.25M+43.5% | -$11.75M+35.7% | -$16.58M+1.2% | -$16.43M+4.9% | -$18.14M-2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neuropace, Inc. generate?
- Neuropace, Inc. (NPCE) generated -$9.9M in operating cash flow over the trailing twelve months.
- What is Neuropace, Inc.'s free cash flow?
- After $412.0K of capital expenditures, Neuropace, Inc.'s free cash flow was -$10.2M over the trailing twelve months, up 43.5% year over year.
- Where does Neuropace, Inc.'s cash flow data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
